(Total Views: 412)
Posted On: 01/25/2021 4:33:33 PM
Post# of 653
$RLFTF DD - Alexandre (copy) We are mentioned! Medicines for lung patients
One of these medicines contains the active ingredient aviptadil. The Swiss company Relief Therapeutics has been developing the medicine for the treatment of acute respiratory distress syndrome (ARDS) for several years and has already reached phase III. Among other things, the medicine has an anti-inflammatory effect and is thought to protect a certain type of lung cell (alveolar type 2 cells), which is particularly important for maintaining lung function, from viral attack. It is now being tested in trials by Relief Therapeutics and NeuroRx (USA) in COVID-19 patients with acute respiratory failure who are receiving intensive care. Interim results suggest that the medicine can significantly reduce the risk of these patients not surviving the disease.
https://www.vfa.de/de/englische-inhalte/thera...s-covid-19
One of these medicines contains the active ingredient aviptadil. The Swiss company Relief Therapeutics has been developing the medicine for the treatment of acute respiratory distress syndrome (ARDS) for several years and has already reached phase III. Among other things, the medicine has an anti-inflammatory effect and is thought to protect a certain type of lung cell (alveolar type 2 cells), which is particularly important for maintaining lung function, from viral attack. It is now being tested in trials by Relief Therapeutics and NeuroRx (USA) in COVID-19 patients with acute respiratory failure who are receiving intensive care. Interim results suggest that the medicine can significantly reduce the risk of these patients not surviving the disease.
https://www.vfa.de/de/englische-inhalte/thera...s-covid-19
(0)
(0)
$MJ
Scroll down for more posts ▼
